[{"address1": "1 Commonwealth Lane, No. 08-22", "city": "Singapore", "zip": "149544", "country": "Singapore", "phone": "65 6250 7738", "website": "https://w2.cytomed.sg", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Chee Kong  Choo", "age": 66, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 27316, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jieming  Zeng M.D., Ph.D.", "age": 50, "title": "Chief Scientific & Medical Officer and Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 89742, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Goh", "age": 34, "title": "Chief Financial Officer", "yearBorn": 1990, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tien Wee  Luk M.D.", "age": 38, "title": "Chief Clinical Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yoong Ying  Tan", "age": 35, "title": "Chief Corporate Officer", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.39, "open": 2.4744, "dayLow": 2.3, "dayHigh": 2.52, "regularMarketPreviousClose": 2.39, "regularMarketOpen": 2.4744, "regularMarketDayLow": 2.3, "regularMarketDayHigh": 2.52, "forwardPE": -14.000001, "volume": 16765, "regularMarketVolume": 16765, "averageVolume": 214471, "averageVolume10days": 1166160, "averageDailyVolume10Day": 1166160, "bid": 2.28, "ask": 2.54, "bidSize": 100, "askSize": 100, "marketCap": 27465202, "fiftyTwoWeekLow": 1.2, "fiftyTwoWeekHigh": 4.3, "priceToSalesTrailing12Months": 61.34802, "fiftyDayAverage": 2.55934, "twoHundredDayAverage": 2.104525, "currency": "USD", "enterpriseValue": 21069516, "floatShares": 3546127, "sharesOutstanding": 11540000, "sharesShort": 82175, "sharesShortPriorMonth": 75557, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0070999996, "heldPercentInsiders": 0.69271004, "heldPercentInstitutions": 0.00043000001, "shortRatio": 2.48, "shortPercentOfFloat": 0.0482, "impliedSharesOutstanding": 11588500, "bookValue": 0.881, "priceToBook": 2.7014759, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -3063187, "trailingEps": -0.21, "forwardEps": -0.15, "enterpriseToRevenue": 47.062, "enterpriseToEbitda": -6.752, "52WeekChange": -0.3887468, "SandP52WeekChange": 0.22408533, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GDTC", "underlyingSymbol": "GDTC", "shortName": "CytoMed Therapeutics Limited", "longName": "CytoMed Therapeutics Limited", "firstTradeDateEpochUtc": 1681479000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5fbb5a07-c64c-3457-b39c-0446de45b69d", "messageBoardId": "finmb_647650276", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.38, "targetHighPrice": 5.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 6822869, "totalCashPerShare": 0.591, "ebitda": -3120472, "totalDebt": 428285, "quickRatio": 19.199, "currentRatio": 21.534, "totalRevenue": 447695, "debtToEquity": 4.215, "revenuePerShare": 0.039, "returnOnAssets": -0.17438, "returnOnEquity": -0.26262, "grossProfits": 447856, "freeCashflow": -2590626, "operatingCashflow": -2555008, "revenueGrowth": -0.211, "grossMargins": 1.00036, "operatingMargins": -7.3597302, "financialCurrency": "SGD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]